Flavonoid compounds: A review of anticancer properties and interactions with cis-diamminedichloroplatinum(II)

Drug Development Research

Volumn 63, Issue 4, 2004, Pages 200-211

  Kosmider, Beata ^a,b   Osiecka, Regina ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Anticancer properties; cis DDP; Flavonoid compounds; Interactions

Indexed keywords

(5 AMINO 2,3 FLUOROPHENYL) 6,8 DIFLUORO 7 METHYL 4H 1 BENZOPYRAN 4 ONE; 3 AMINOFLAVONE CISPLATIN COMPLEX; AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; ANTIBODY CONJUGATE; ASTRAGALIN; B43 GENISTEIN; BIS(3 AMINOFLAVONE)DICHLOROPLATINUM; BUTEIN; CISPLATIN; CISPLATIN DERIVATIVE; DNA; EPIDERMAL GROWTH FACTOR GENISTEIN; EUPATILIN; FLAVAN 3 OL; FLAVANONE; FLAVANONOL; FLAVONE; FLAVONOID; FLAVONOL; FLAVOPIRIDOL; GENISTEIN; ISOFLAVONE; QUERCETIN; TANNIN; TRICIN; UNCLASSIFIED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BONE MARROW TOXICITY; CANCER CELL; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COMPLEX FORMATION; CYTOTOXICITY; DIARRHEA; DRUG DNA BINDING; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; GENOTOXICITY; HUMAN; HYPOMAGNESEMIA; LEUKOPENIA; LUNG CANCER; NAUSEA; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PERIPHERAL NEUROPATHY; REVIEW; SECOND CANCER; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; VOMITING;

EID: 16344370794     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10421     Document Type: Review

References (94)

1. Arora A, Nair MG, Strasburg GM. 1998. Structure-activity relationship for antioxidant activities of a series of flavonoids in a liposomal system. Free Rad Biol Med 24:1355-1363.
2. Bates S, Vousden KH. 1999. Mechanisms of p53-mediated apoptosis. Cell Mol Life Sci 55:28-37.
3. Bible KC, Kaufmann SH. 1996. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res 56:4856-4861.
4. Bible KC, Bible RH Jr, Kottke TJ, Svingen PA, Xu K, Pang Y-P, Hajdu E, Kaufmann SH. 2000a. Flavopiridol binds to duplex DNA. Cancer Res 60:2419-2428.
5. Bible KC, Boerner SA, Kirkland K, Anderi KL, Bartelt D Jr, Svingen PA, Kottke TJ, Lee YK, Eckdahl S, Stalboerger PG, Jenkins RB, Kaufmann SH. 2000b. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. Clin Cancer Res 6:661-670.
6. Boeg F, Strau T, Keh A, Boesenberg C, Christiansen K, Andersen A, Jakob F, Köhrle J. 1996. Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I. J Biol Chem 271:2262-2270.
7. Borner MM, Jonocourt F, Hotz MA. 1997 Similarity of apoptosis induction by 2-chlorodeoxyadenosine and cisplatin in human mononuclear blood cells. Br J Cancer 76:1448-1454.
8. Choi J-A, Kim J-Y, Lee J-Y, Kang C-M, Kwon H-J, Yoo Y-D, Kim T- W, Lee Y-S, Lee S-J. 2001. Induction of cell cycle arrest and apoptosis in human breast cancer cells by quercetin. Int J Oncol 19:837-844.
9. Ciesielska E, Studzian K, Zyner E, Ochocki J, Szmigiero L. 2000. DNA damage and apoptosis induction in L1210 cells by cis-diamminedichloroplatinum (II) and its new aminoflavone analogue. Cell Mol Biol Lett 5:441-450.
10. Čipák L, Rauko P, Miadoková E, Čipá ková I, Navotný L. 2003. Effects of flavonoids on cisplatin-induced apoptosis of HL-60 and L1210 leukemia cells. Leuk Res 27:65-72.
11. Conklin KA. 2000. Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer 37:1-18.
12. Dancey J, Le Chevalier T. 1997. Non-small cell lung cancer: an overview of current management. Eur J Cancer 33:S2-S7.
13. Di Carlo G, Mascolo N, Izzo AA, Capasso F. 1999. Flavonoids: old and new aspects of a class of natural therapeutic drugs. Life Sci 65:337-353.
14. Dixon RA, Ferreira D. 2002. Genistein. Phytochemistry 60:205-211.
15. Duthie SJ, Collins AR, Duthie GG, Dobson VL. 1997. Quercetin and myricetin protect against hydrogen peroxide-induced DNA damage (strand breaks and oxidized pyrimidines) in human lymphocytes. Mutat Res 393:223-231.
16. Fan J, Bertino JR. 1999. Modulation of cisplatinum cytotoxicity by p53: effect of p53-mediated apoptosis and DNA repair. Mol Pharmacol 56:966-972.
17. Ferguson LR, Baguley BC. 1996. Mutagenicity of anticancer drugs that inhibit topoisomerase enzymes. Mutat Res 355:91-101.
18. Ferguson LR, Pearson AE. 1996. The clinical use of mutagenic anticancer drugs. Mutat Res 355:1-12.
19. Gebel T, Lantzsch H, Plessow K, Dunkelberg H. 1997. Genotoxicity of platinum and palladium compounds in human and bacterial cells. Mutat Res 389:183-190.
20. Ghalaut VS, Kharb S, Ghalaut PS, Rawal A. 1999. Lymphocyte glutathione levels in acute leukemia. Clin Chim Acta 285:85-89.
21. Gonzalez VM, Fuertes MA, Alonso C, Perez JM. 2001. Is cisplatin-induced cell death always produced by apoptosis. Mol Pharmacol 59:657-663.
22. Goto S, Yoshida K, Morikava T, Urata Y, Suzuki K, Kondo T. 1995. Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells. Cancer Res 55:4297-4301.
23. Gridelli C, Perrone F, Monfardini S. 1998. Are platinum compounds mandatory in the treatment of metastatic non-small cell lung cancer? Contra. Eur J Cancer 34:1993-1999.
24. Hagopian GS, Mills GB, Khokhar AR, Bast RC Jr, Siddik ZH. 1999. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato) (dichloro)-platinum(IV). Clin Cancer Res 5:655-663.
25. Hofmann J, Fiebig HH, Winterhalter BR, Berger DP, Grunicke H. 1990. Enhancement of the antiproliferative activity of cis- diamminedichloroplatinum(II) by quercetin. Int J Cancer 45:536-539.
26. Ishikawa T, Ali-Osman F. 1993. Glutathione-associated cis-diammine-dichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. J Biol Chem 268:20116-20125.
27. Jakubowicz-Gil J, Paduch R, Gawron A, Kandefer-Szerszeñ M. 2002. The effect of heat shock, cisplatin, etoposide and quercetin on Hsp27 expression in human normal and tumour cells. Folia Histochem Cytobiol 40:31-35.
28. Jakupec MA, Galanski M, Keppler BK. 2003. Tumour-inhibiting platinum complexes: state of the art and future perspectives. Rev Physiol Biochem Pharmacol 146:1-53.
29. Jamieson ER, Lippard SJ. 1999. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99:2467-2498.
30. Jansen BAJ, Perez JM, Pizarro A, Alonso C, Reedijk J, Navarro-Ranninger C. 2001. Sterically hindered cisplatin derivatives with multiple carboxylate auxiliary arms: synthesis and reactions with guanosine-5′-monophosphate and plasmid DNA. J Inorg Biochem 85:229-235.
31. Järvinen K, Pietarinen-Runtti P, Linnainmaa K, Raivio KO, Krejsa CM, Kavanagh T, Kinnula VL. 2000. Antioxidant defense mechanisms of human mesothelioma and lung adenocarcinoma cells. Am J Physiol Lung Cell Mol Physiol 278:L696-L702.
32. Jaskula-Sztul R. 2000. Polymorphism in detoxifying enzymes. Post Bioch 46:50-59.
33. Johnstone RW, Ruefli AA, Lowe SW. 2002. Apoptosis: a link between cancer genetics and chemotherapy. Cell 108:153-164.
34. Jordan P, Carmo-Fonesca M. 2000. Molecular mechanisms involved in cisplatin cytotoxicity. CMLS 57:1229-1235.
35. Kartalou M, Essigmann JM. 2001a. Mechanisms of resistance to cisplatin. Mutat Res 478:1-21.
36. Kartalou M, Essigmann JM. 2001b. Mechanisms of resistance to cisplatin. Mutat Res 478:23-43.
37. Kasahara K, Fujiwara Y, Nishio K. Ohmori T, Sugimoto Y, Komiya K, Matsuda T, Saijo N. 1991. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. Cancer Res 51:3237-3242.
38. Kawakami K, Tsukuda M, Mizuno H, Nishimura G, Ishii A, Hamajima K. 1999. Alteration of the Bcl-2/Bax status of head and neck cancer cell lines by chemotherapeutic agents. Anticancer Res 19:3927-3932.
39. Kelland LR. 2000. Preclinical perspectives on platinum resistance. Drugs 59:1-8.
40. Kornarova EA, Gudkov AV. 2001. Chemoprotection from P53-dependent apoptosis: potential clinical application of the p53 inhibitors. Biochem Pharmacol 62:657-667.
41. Kosmider B, Osiecka R, Ciesielska E, Szmigiero L, Zyner E, Ochocki J. 2004a. Induction of apoptosis and necrosis in lymphocytes by the cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP. Mutat Res 558:169-179.
42. Kosmider B, Wyszynska K, Janik-Spiechowicz E, Osiecka R, Zyner E. Ochocki J, Ciesielska E, Wasowicz W. 2004b. Evaluation of the genotoxicity of cis-bis(3-aminoflavone) dichloroplatinum(II) in comparison with cis-DDP. Mutat Res 558:93-110.
43. Kosmider B, Zyner E, Osiecka R, Ochocki J. 2004c. Genotoxicity of cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP in A549 cells evaluated by the comet assay. Can J Physiol Pharm 82:353-358.
44. Kosmider B, Zyner E, Osiecka R, Ochocki J. 2004d. Induction of apoptosis and necrosis in A549 cells by the cis-Pt(II) complex of 3-aminoflavone in comparison with cis-DDP. Mutat Res 563:61-70.
45. Kosmider B, Osiecka R, Zyner E, Ochocki J. 2005. Comparison between the genotoxicity of cis-Pt(II) complex of 3-aminoflavone and cis-DDP in lymphocytes evaluated by the comet assay. Drug Chem Toxicol. In press.
46. Krol W, Czuba ZP, Threadgill MD, Cunningham BDM, Pietsz G, 1995. Inhibition of nitric oxide (NO) production in murine macrophages by flavones. Biochem Pharmacol 50:1031-1035.
47. Kuffel MJ, Schroeder JC, Pobst LJ, Naylor S, Reid JM, Kaufmann SH, Ames MM. 2002. Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol 62:143-153.
48. Kuntz S, Wenzel U, Daniel H. 1999. Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity, and apoptosis in human colon cancer cell lines. Eur J Nutr 38:133-142.
49. Lam V, McPherson JP, Salmena L, Lees J, Chu W, Sexsmith E, Hedley DW, Freedman MH, Reed JC, Malkin D, Goldenberg GJ. 1999. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin. Leukemia Res 23:871-880.
50. Lloyd D. 2002. The role of DNA adduct structure and conformation in cisplatin resistance. Trends Pharmacol Sci 23:158.
51. Magnani L, Gaydou EM, Hubaud JC. 2000. Spectrophotometric measurement of antioxidant properties of flavones and flavonols against superoxide anion. Anal Chim 411:209-216.
52. Makin G, Dive C. 2001. Apoptosis and cancer chemotherapy. Trends Cell Biol 11:S22-S26.
53. Marverti G, Andrews PA. 1996. Stimulation of cis- diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulation-defective resistant cells. Clin Cancer Res 2:991-999.
54. 2-M. Cancer Res 53:1328-1331.
55. Matsushima H, Yonemura K, Ohishi K, Hishida A. 1998. The role of oxygen free radicals in cisplatin-induced acute renal failure in rat. J Lab Clin Med 131:518-526.
56. Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vies EGE. 1992. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 52:6885-6889.
57. Merk O, Speit G. 1999. Detection of crosslinks with the comet assay in relationship to genotoxicity and cytotoxicity. Environ. Mol. Mutagen 33:167-172.
58. Mistry P, Kelland LR, Abel G, Sindhar S, Harrap KR. 1991. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melaphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64:215-220.
59. Narayana KR, Reddy MS, Chaluvadi MR, Krishna DR. 2001. Bioflavonoids classification, pharmacological, biochemical, effects and therapeutic potential. Indian J Pharmacol 33:2-16.
60. Nijhoff WA, Bosboom MA, Smidt MH, Peters, WHM. 1995. Enhancement of rat hepatic and gastrointestinal glutathione and glutathione S-transferases by α-angelicalactone and flavone. Carcinogenesis 16:607-612.
61. Nijveldt RJ, Nood E, Hoorn DEC, Boelens PG, Norren K, Leeuwen PAM. 2001. Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr 74:418-425.
62. O'Brien ML, Tew KD. 1996. Glutathine and related enzymes in multidrug resistance. Eur J Cancer 32A:967-978.
63. O'Dwyer PJ, Stevenson JP, Johnson SW. 1999. Clinical status of cisplatin, carboplatin and other platinum-based antitumor drugs. In: Lippert B, editor. Cisplatin: chemistry and biochemistry of a leading anticancer drug. Zürich, Weinheim: Verlag, Helv Chim Acta, Wiley-VCH. p 31-69.
64. Ochocki J, Zyner E. 2003. PL Patent Nr P.185585.
65. Oliński R, Zastawny TH. 1991. Reactions with DNA of an antitumor drug cis-diamminedichloroplatinum (II). Post Bioch 37:40-47.
66. Ormerod MG, O'Neill C, Robertson D, Kelland LR, Harrap KR. 1996. Cis-diamminedichloroplatiuum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 37:463-471.
67. Pietras T, Kakowski R, Zyner E, Stolarek R, Ochocki J, Musiał A, Nowak D, Glinka R. 1998. Deoxyribose degradation by cis-platinum and its derivatives choline, hydroaspartate and aminoflavone. J Cosmetol 4:177-180.
68. Priya SD, Devi CSS. 1999. Protective effect of quercetin in cisplatin-induced cell injury in the rat kidney. Indian J Pharmacol 31:422-426.
69. Prokop A, Wieder T, Sturm I, Essmann F, Seeger K, Wuchter C, Ludwig W-D, Henze G, Dörken B, Daniel PT. 2000. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 14:1606-1613.
70. Puhakka A, Ollikainen T, Soini Y, Kahlos K, Säily M, Koistinen P. Pääkko P, Linnainmaa K, Kinnula VL. 2002. Modulation of DNA single-strand breaks by intercellular glutathione in human lung cells exposed to asbestos fibres. Mutat Res 514:7-17.
71. Reedijk J. 1999. Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? Chem Rev 99:2499-2510.
72. Rice-Evans CA, Nicholas J, Miller J, Paganga G. 1997. Antioxidant properties of phenolic compounds. Trends Plant Sci 2:152-159.
73. Rosenberg B, Van Camp L, Krigas T. 1965. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205:698-699.
74. Rosenberg B, Van Camp L, Trosko JE, Mansour VH. 1969. Platinum compounds: a new class of potent antitumor agents. Nature 222:385-386.
75. Russo A, DeGraff W, Friedman N, Mitchell JB. 1986. Selective modulation of glutathione levels in human normal versus tumor cells and subsequent differential response to chemotherapy drugs. Cancer Res 46:2845-2848.
76. Sakagami H, Jiang Y, Kusama K, Atsumi T, Ueha T, Toguchi M, Iwakura I, Satoh K, Fukai T, Nomura T. 2000. Induction of apoptosis by flavones, flavonols (3-hydroxyflavones) and isoprenoid-substituted flavonoids in human oral tumor cell lines. Anticancer Res 20:1-278.
77. Salti GI, Grewal S, Mehta RR, Das Gupta TK, Boddie AW Jr, Constantinou AI. 2000. Genistein induces apoptosis and topoisomerase II-mediated DNA breakage in colon cancer cells. Eur J Cancer 36:796-802.
78. Schoenlein PV, Barrett JT, Welter D. 1999. The degradation profile of extrachromosomal circular DNA during cisplatin-induced apoptosis is consistent with preferential cleavage at matrix attachment regions. Chromosoma 108:121-131.
79. Seo H-J, Surh Y-J. 2001. Eupatilin, a pharmacologically active flavone derived from Artemisia plants, induces apoptosis in human promyelocytic leukemia cells. Mutat Res 496:191-198.
80. Shao Z-M, Wu J, Shen Z-Z, Barsky SH. 1998. Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res 58:4851-4857.
81. Shapiro GI, Koestner DA, Matranga CB, Rollins BJ. 1999. Flavopiridol induces cell cycle arrest and P53-independent apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 5:2925-2938.
82. Strobel T, Swanson L, Korsmeyer S, Cannistra SA. 1996. BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci U S A 93:14094-14099.
83. Traganos F, Ardelt B, Halko N, Bruno S, Darzynkiewicz Z. 1992. Effects of genistein on the growth and cell cycle progression of normal human lymphocytes and human leukemic MOLT-4 and HL-60 cells. Cancer Res 52:6200-6208.
84. Tsuruta Y, Mandai M, Konishi I, Kuroda H, Kusakari T, Yyra Y, Hamid AA, Tamura I. Kariya M, Fujii S. 2001. Combination effect of adenovirus-mediated pro-apoptotic box gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines. Eur J Cancer 37:531-541.
85. Wang HK. 2000. The therapeutic potential of flavonoids. Expert Opin Investig Drug 9:2103-2119.
86. Wei Y, Zhao X, Kariya Y, Fukata H, Teshigawara K, Uchida A. 1994. Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res 54:4952-4957.
87. Weijl NI, Clenton FJ, Osanto S. 1997. Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev 23:209-240.
88. Weiss RB, Christian MC. 1993. New cisplatin analogues in development. Drugs 46:360-377.
89. Wenzel U, Kuntz S, Brendel MD, Daniel H. 2000. Dietary flavone is a potent inducer in human colon carcinoma cells. Cancer Res 60:3823-3831.
90. Win W, Cao Z, Peng X, Trush M, Li Y. 2002. Different effects of genistein and resveratrol on oxidative DNA damage in vitro. Mutat Res 513:113-120.
91. Wong E, Giandomenico CM. 1999. Current status of platinum-based antitumor drugs. Chem Rev 99:2451-2466.
92. Zhang K, Chew M, Yang EB, Wong KP, Mack P. 2001. Modulation of cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms. Mol Pharmacol 59:837-843.
93. Zhou Y, Lee AS. 1998. Mechanism for the suppression of the mammalian stress response by genistein, an anticancer phytoestrogen from soy. J Natl Cancer Inst 90:381-388.
94. Zyner E, Graczyk J, Ochocki J. 1999. Pt(II) and Pd(II) complexes of 3-aminoflavone: in vitro and in vivo evaluation. Pharmazie 54:945-946.